|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Herceptin® Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer
Researchers at the National Cancer Institute have reported their findings from two large randomized clinical trials on early-stage HER-2 postitive breast cancer.
Patients are considered "HER-2 positive" if their cancer cells "overexpress," or make too much of, a protein called HER-2, which is found on the surface of cancer cells…These tumors tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER-2…
|home spotlight commentary research events news about contact links archives|